NASDAQ · Biotechnology

PLRZ (PLRZ) Stock

$11.06 -3.74% NASDAQ: PLRZ Healthcare

Valuation

MetricValue
Price$11.06
Market Cap$12.39M
P/E Ratio-6.55
P/B Ratio0.72
P/S Ratio0.00
EPS (TTM)$-2.07
52-Week High$18.20
52-Week Low$2.88
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-14.29%
ROA-14.29%
ROCE-28.57%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio29.03

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-1.0M$-1.0M$-1.0M$-6.0M
Net Profit$-1.0M$-1.0M$-1.0M$-2.0M$-3.0M
EPS$0.00$0.00$0.00$-134.14$-2.07
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.0M$1.0M$1.0M$6.0M$21.0M
Total Liabilities$1.0M$1.0M$1.0M$0$0
Cash$1.0M$0$0$3.0M$1.0M
Borrowings$0$0$0$0$0

Latest News

Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) InvestorsHub · Jul 2, 2026 Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial GlobeNewswire · Jul 2, 2026 Polyrizon Receives Approval for Human Trial of Nasarix Nasal Spray for Allergic Rhinitis MT Newswires · Jun 29, 2026 Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial GlobeNewswire · Jun 29, 2026 Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform GlobeNewswire · Jun 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0$-1.0M$-1.0M$-1.0M$-5.0M
Investing Cash Flow$0$0$0$0$-17.0M
Financing Cash Flow$0$-1.0M$0$0$0
Net Cash Flow$1.0M$0$0$3.0M$-1.0M
Free Cash Flow$-1.0M$-1.0M$-1.0M$-1.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-23.22%
Quick Ratio29.03
Interest Coverage-2.00
Return 1Y109.46%
Return 3Y—
Return 5Y—

Ownership

Insiders Held0.83%
Institutions Held7.13%
Institutions Float Held7.19%
Institutional HolderSharesReport Date
Citadel Advisors Llc10,1492026-03-31
Legacy Wealth Managment, LLC/ID1,1502026-03-31
Citigroup Inc.12026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AIM $0.24 -5.84% -0.09 $801193 0.00%
CYCN $3.57 +0.28% -2.99 $16.71M 0.00%
KTTA $0.45 -2.17% -0.25 $3.35M 0.00%
NBYNovaBay Pharmaceuticals, Inc. $1.47 -24.62% 0.09 $39.14M 2.72%
PMCB $0.59 +0.00% 0.24 $4.01M 0.00%

About PLRZ

PLRZ is led by CEO Tomer Izraeli, employs 2 people, headquartered in IL, publicly traded since 2024.

PLRZ stock trades at $11.06 with a market capitalization of $12.39M. The stock is valued at a price-to-earnings (P/E) ratio of -6.55, price-to-book of 0.72, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.88 and $18.20, and currently trades 39.2% below its 52-week high.

On profitability, PLRZ generates a return on equity (ROE) of -14.29%, return on capital employed of -28.57%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides